



PRESS RELEASE

SYNAIRGEN PLC
(‘Synairgen’ or the ‘Company’)

Contract Signed To Advance Growth Factor Programme

Synairgen, the company developing novel therapies for asthma and COPD, today announces that it has selected Alpha Biologics in connection with the advancement of its growth factor drug development programme.

Alpha Biologics, Cambridge, UK, is an independent contract biomanufacturing organisation offering FDA/EMA cGMP compliant services to the worldwide pharmaceutical and biotechnology industry. Synairgen is working with Alpha Biologics to develop a scalable manufacturing process for Synairgen’s optimised growth factor to support pre-clinical and clinical development.

Richard Marsden, Synairgen’s Managing Director, said, “We have significant confidence in our growth factor drug development programme for asthma to restore barrier function in patients. Initiating the development of a scalable manufacturing process is another significant milestone for the programme.”

“We are pleased to be associated with such an exciting programme from a company at the forefront in their field”, said Alpha’s CEO, Mr Simon Saxby.

-Ends-

For further information, please contact:

Synairgen

Richard Marsden, Managing Director

John Ward, Finance Director

Tel: + 44 (0) 2380 512 800

Alpha Biologics

Jon Mowles, Commercial Director

Tel: + 44 (0) 1223 496 070

The Hogarth Partnership (Synairgen Media Enquiries) Tel: + 44 (0) 20 7357 9477

Melanie Toyne-Sewell

Notes to Editors

About Synairgen

Synairgen is a drug discovery company founded by Professors Stephen Holgate, Donna Davies and Ratko Djukanovic, focused on identifying and out-licensing new pharmaceutical products which address the underlying causes of asthma and chronic obstructive pulmonary disease. Synairgen is listed on AIM (LSE: SNG).

For more information about Synairgen, please see www.synairgen.com.

About Synairgen's Growth Factor Programme

Synairgen's researchers have found that the cells which line the airways (the epithelium) of asthmatics do not form a robust barrier. This defect in barrier function may be a key contributor to asthma susceptibility enabling known triggers of asthma, such as allergens, pollutants and viruses, to penetrate through the epithelium to the underlying tissue. Using asthmatic epithelial cells from its biobank of human tissue, Synairgen has developed a modified growth factor that can restore barrier function.

About Alpha Biologics

Alpha Biologics is an independent contract biomanufacturing organisation offering FDA/EMA cGMP compliant services to the worldwide pharmaceutical and biotechnology industry. Initial process development is undertaken in Cambridge, England, before being transferred to scale up facilities for final process technology transfer and manufacturing of biologics drugs for pre-clinical and clinical trials. The company is headquartered in Malaysia. For more information, please see www.alphabiologics.com.